Copeland Capital Management LLC Sells 88,686 Shares of LeMaitre Vascular, Inc. $LMAT

Key Points

• Copeland Capital Management LLC has reduced its stake in LeMaitre Vascular, Inc. by 8.2% after selling 88,686 shares, leaving them with a total of 990,037 shares.
• Institutional investors hold 84.64% of LeMaitre Vascular's stock, with several other firms increasing their positions, including Goldman Sachs Group Inc., which raised its holdings by 27.0%.
• LeMaitre Vascular recently announced a $0.20 quarterly dividend, with a 0.9% dividend yield, while the company's stock has shown a strong performance with a revenue increase of 15.0% compared to the same quarter last year.

Copeland Capital Management LLC lowered its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 8.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 990,037 shares of the medical instruments supplier's stock after selling 88,686 shares during the period. LeMaitre Vascular makes up about 1.7% of Copeland Capital Management LLC's investment portfolio, making the stock its 6th biggest position. Copeland Capital Management LLC owned approximately 4.38% of LeMaitre Vascular worth $82,223,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Congress Asset Management Co. grew its holdings in shares of LeMaitre Vascular by 4.6% in the 2nd quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier's stock worth $55,973,000 after acquiring an additional 29,553 shares during the period. Northern Trust Corp grew its holdings in shares of LeMaitre Vascular by 5.4% in the 1st quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier's stock worth $28,993,000 after acquiring an additional 17,748 shares during the period. Envestnet Asset Management Inc. grew its holdings in shares of LeMaitre Vascular by 9.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier's stock worth $23,921,000 after acquiring an additional 25,680 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of LeMaitre Vascular by 11.6% in the 1st quarter. Russell Investments Group Ltd. now owns 264,261 shares of the medical instruments supplier's stock worth $22,172,000 after acquiring an additional 27,470 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of LeMaitre Vascular by 27.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier's stock worth $22,019,000 after acquiring an additional 55,804 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on LMAT shares. Cantor Fitzgerald increased their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Barrington Research reiterated an "outperform" rating and set a $95.00 target price on shares of LeMaitre Vascular in a report on Tuesday, September 23rd. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $97.60.

Insider Transactions at LeMaitre Vascular

In related news, Director David B. Roberts sold 10,815 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total value of $999,197.85. Following the transaction, the director directly owned 17,976 shares of the company's stock, valued at approximately $1,660,802.64. This trade represents a 37.56% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the sale, the director owned 2,916 shares of the company's stock, valued at approximately $274,104. This represents a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 120,815 shares of company stock valued at $11,280,206. Corporate insiders own 9.50% of the company's stock.

LeMaitre Vascular Trading Up 0.2%

Shares of LeMaitre Vascular stock opened at $86.87 on Friday. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The firm has a market cap of $1.97 billion, a PE ratio of 42.17, a P/E/G ratio of 2.23 and a beta of 0.78. The business's fifty day moving average is $91.55 and its two-hundred day moving average is $86.25. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. The company had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The business's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were given a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular's dividend payout ratio (DPR) is 38.83%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.